Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 10:20 PM
Ignite Modification Date:
2025-12-24 @ 10:20 PM
NCT ID:
NCT06815835
Eligibility Criteria:
Inclusion Criteria:
* The participant must satisfy all the following criteria to be eligible for enrolment:
* Healthy infant participants of either gender aged\* 9 to 12 months at the time of enrollment
* Participants should be in good health as determined by the medical history and physical examination based on the clinical judgment of the investigator
* No previous history of vaccination against measles, rubella, or Yellow fever
* Written informed consent from the participant's parent/guardian
* Participant's parent/guardian literate enough to fill the diary card \*Age calculated as per completed month
Exclusion Criteria:
* Participants positive for serological markers against Dengue and/or Japanese Encephalitis infections
* History of hypersensitivity reaction to any component of the study vaccines including egg and chicken proteins
* History of hypersensitivity reaction to neomycin
* History of laboratory-confirmed or suspected measles, rubella, or Yellow fever in the past
* Participant exposed# to measles, rubella, or Yellow fever virus within the past 30 days
* Fever of any origin or infectious disorder of 3 days or more within the past month
* Febrile illness (axillary temperature ≥37.5°C) at the time of enrollment
* History of any vaccination within the past month
* Clinically significant systemic disorders such as cardiovascular, respiratory, neurologic, gastrointestinal, hepatic, renal, endocrine, haematological, immunological, or metabolic disorder
* Confirmed or suspected immunosuppressive or immunodeficiency disorder; or participants on any immunosuppressive or immunostimulant therapy
* Known case of thrombocytopenia or any coagulation disorder, or participants on anticoagulation therapy
* Participants administered blood, blood-containing products, or immunoglobulins within the last 3 months or planned administration during the study
* Participant participated in another clinical study in the past 3 months
* Any other reason for which the investigator feels that the participant should not participate #Close contact (family member or neighbour) with laboratory-confirmed or clinical diagnosis of measles/rubella/Yellow fever
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
9 Months
Maximum Age:
12 Months
Study:
NCT06815835
Study Brief:
Protocol Section:
NCT06815835